Philadelphia, Pennsylvania
CNS clinical trials in Philadelphia, PA
97 CNS studies are recruiting participants at sites in Philadelphia as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Philadelphia at a glance
- 97 studies are recruiting at a site in Philadelphia.
- By phase: Early Phase 1 (5), Phase 1 (2), Phase 1/2 (3), Phase 2 (13), Phase 3 (33), Phase 4 (6), No phase (18), Observational (17). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (54), university, hospital or other (39), government (4).
- By research area: Depression (31), Parkinson's Disease (21), Epilepsy (17), Migraine (10), Schizophrenia (7), Multiple Sclerosis (5), ADHD (4), Bipolar Disorder (2).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Philadelphia
Basic details from each study's public record (the 30 most recently updated of 97). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Postpartum Care in the NICU (PeliCaN) Transitions
- No phase
- Ages 16 and older
- Female participants
- Sponsor
- University of Pennsylvania
- Study site
- Hospital of the University of Pennsylvania
- Registry record
- NCT06521398 · updated
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Study sites
- Adams Clinical Philadelphia · Flourish Research Philadelphia
- Registry record
- NCT06793397 · updated
Precision Depression Adalimumab Trial
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Daniel Moriarity
- Study site
- University of Pennsylvania
- Registry record
- NCT07845604 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study site
- University of Pennsylvania
- Registry record
- NCT07002034 · updated
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Definium Therapeutics US, Inc.
- Study site
- Adams Clinical Philadelphia
- Registry record
- NCT07592689 · updated
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Penn Medicine: University of Pennsylvania Health System
- Registry record
- NCT07412756 · updated
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- University of Pennsylvania - Perelman School of Medicine
- Registry record
- NCT05850689 · updated
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University of Pennsylvania
- Registry record
- NCT06559306 · updated
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- University of Pennsylvania
- Registry record
- NCT07573176 · updated
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study sites
- Adams Clinical Philadelphia · Penn Medicine: University of Pennsylvania Health System
- Registry record
- NCT07775300 · updated
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Neurocrine Biosciences
- Study site
- Neurocrine Clinical Site
- Registry record
- NCT06966401 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Schizophrenia studies recruiting in Philadelphia
A Study to Evaluate the Effect of KarXT on Urological Safety
- Phase 4
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Adams Clinical Philadelphia
- Registry record
- NCT07221877 · updated
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Perelman School of Medicine at the University of Pennsylvania
- Registry record
- NCT07379827 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Bipolar disorder studies recruiting in Philadelphia
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
- Phase 2
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Penn Medicine: University of Pennsylvania Health System
- Registry record
- NCT07286175 · updated
Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Philadelphia, PA on ClinicalTrials.gov.
ADHD studies recruiting in Philadelphia
The Myelin Disorders Biorepository Project
- Observational
- All ages
- All sexes
- Sponsor
- Children's Hospital of Philadelphia
- Study sites
- The Children's Hospital of Philadelphia · University of Pennsylvania
- Registry record
- NCT03047369 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Philadelphia
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- AstraZeneca
- Registry record
- NCT06989112 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Hospital of the University of Pennsylvania ( Site 5007)
- Registry record
- NCT06952504 · updated
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
- Phase 2
- Ages 50 to 80
- All sexes
- Sponsor
- Yale University
- Study site
- University of Pennsylvania
- Registry record
- NCT06996652 · updated
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Honickman Center ( Site 5033)
- Registry record
- NCT07216703 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- University Pennsylvania Hospital
- Registry record
- NCT07174310 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- Thomas Jefferson University Hospital
- Registry record
- NCT06680830 · updated
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010)
- Registry record
- NCT04165070 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Epilepsy studies recruiting in Philadelphia
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Rapport Therapeutics Inc.
- Registry record
- NCT07563881 · updated
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- Phase 3
- Ages 4 to 55
- All sexes
- Sponsor
- SK Life Science, Inc.
- Study site
- Children's Hospital of Philadelphia
- Registry record
- NCT05219617 · updated
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Xenon Pharmaceuticals Inc.
- Study site
- University of Pennsylvania
- Registry record
- NCT05667142 · updated
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
- Phase 1/2
- Ages 2 to 12
- All sexes
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Study site
- The Children's Hospital of Philadelphia (CHOP)
- Registry record
- NCT07531745 · updated
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Neurona Therapeutics
- Study site
- Thomas Jefferson University Hospital
- Registry record
- NCT05135091 · updated
Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Migraine studies recruiting in Philadelphia
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Phase 4
- Ages 18 to 70
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- University of Pennsylvania
- Registry record
- NCT06972056 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Clinical Research Philadelphia
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Clinical Research Philadelphia
- Registry record
- NCT07674654 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Philadelphia, PA on ClinicalTrials.gov.
Ask about studies near Philadelphia
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Pennsylvania
All Pennsylvania locations
162 studies recruiting across 42 cities.
Pittsburgh
56 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections